Evaluation of primary intravenous methyl prednisolone pulse treatment in the prevention of coronary artery abnormality in children with Kawasaki disease

Tehran University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2020年1月13日

试验速览

暂无简介。

•Kawasaki disease definition according to American Heart Assosiation (AHA): Complete Kawasaki disease : Fever for more than 5 days plus at least four of the following clinical signs : Bilateral conjunctival injection, Changes in the oropharyngeal mucous membranes, including one or moreof injected and/or fissured lips, strawberry tongue, injected pharynx ,Changes in the peripheral extremities, including erythema and/or edema of the hands and feet (acute phase) or periungual desquamation (convalescent phase), Polymorphous rash, Cervical lymphadenopathy with at least one node >1.5 cm
•Incomplete Kawasaki : Fever for more than 5 days plus fewer than 4 of the principal clinical findings, and compatible laboratory or echocardiographic findings.

•Complicated disease( Macrophage Activating Syndrome)
•Patients with frequent KD
•Patients with Coronary Artery Abnormality have already been approved
•Congestive Heart Failure
•Chronic renal failure
•Sensitization to Methyl Prednisolone or Prednisolone
•Active viral viral zoster infection; or exposure to Varicella in the past 21 days if not safe
•Injection of Oral, Intravenous or Muscular Corticosteroids> 3 days in the last 7 days
•History of severe reaction to the preparation of any human globulin product
•Registering in another study that may affect the effects of treatment, effectiveness, or follow-up.

发起方